samedan logo
 
 
 
spacer
home > ebr > summer 2018 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

The first documented administration of insulin as an intervention in diabetes was in 1922. A relatively crude extract from bovine pancreas was injected into a 14-year-old boy in Toronto, and, although the first injection was not entirely without complications, this intervention ultimately saved his life. The subsequent impact of this discovery on the lives of countless patients and our industry has been, to say the least, transformational. Fast forward a century to 2022, and the biosimilars of biopharmaceutically manufactured, synthetic insulins will likely be mainstay therapies for diabetes, as Syneos Health's Rafal Kokolus, Dr Doug Niven, and Rohit Sood discuss how the illness joins the list of conditions for which all stakeholders are transitioning towards biosimilar adoption.

If the rapidly expanding and often complex biosimilars universe is not quite fully in focus for you yet, then articles in the summer 2018 edition of EBR will provide excellent overviews of the state-of- the-art in defining by sequence (Dr Richard Easton and Dr Andrew Reason at BioPharmaSpec) and protecting via optimal patent and commercial strategies for these high-value ‘affordable’ biological therapeutics, distinct in sequence and synthesis, yet ‘highly similar’ in efficacy and safety to first generation proprietary forms of which they are effectively ‘functional generics’ (Boult Wade Tennant’s Jennifer O’Farrell, and Finnegans’ Sanya Sukduang and Thomas J Sullivan).

The first ever biosimilar drug product approval (by the EMA in 2006) was for a hormone therapy, omnitrope (somatropin), although the first biosimilar insulin hormone was only approved as recently as 2014. Antibody biosimilars, ‘adopted’ by the EMA and FDA more recently, have made much more ‘noise’, arguably because of the premium priced proprietary market pioneers they can replace. Three articles in this edition of EBR focus on antibodies as the targeting component of antibody-drug conjugates (ADCs) in cancer therapy (the team from Aptamer Group, and Dr Neil Butt from IONTAS). ADCs are an increasingly important drug class in oncology, evidenced by the fact that, according to Professor Andreas Pahl from Heidelberg Pharma, more than 70 are now in clinical trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O'Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Injection vials for vaccines for protection against Covid-19

Düsseldorf, July 02, 2020 The vaccines under development to protect against Covid-19 are, like many other drugs, filled in so-called injection or vials made of type 1 borosilicate glass, also known as vials. The large worldwide demand for vials is met by the Gerresheimer Group's plants in Europe, America and Asia, where they are manufactured to high quality standards for customers in the pharmaceutical industry. The Company has already received initial orders for vials for drugs and vaccines against Covid-19.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement